Horizon Space Acquisition Ii CORP

Horizon Space Acquisition II Corp. has secured a one-month extension to complete its initial business combination by depositing $50,000 into its trust account.

Horizon Space Acquisition II Corp. announced a $7.8 million PIPE financing to support its business combination with SL Bio Ltd., forming a new public entity, SL Science Holding Limited.

Horizon Space Acquisition II Corp. extended its deadline to complete a business combination with SL BIO Ltd. to April 18, 2026, funded by a $50,000 unsecured promissory note from William Wang.

Horizon Space Acquisition II Corp. secured a one-month extension to complete its business combination with SL Bio Ltd. but faces substantial public share redemptions.

Horizon Space Acquisition II Corp. announced additional independent director nominees and updated beneficial ownership details for its upcoming business combination with SL BIO Ltd.

Horizon Space Acquisition II Corp. issued a press release clarifying the redemption process for shareholders ahead of its proposed business combination with SL BIO Ltd. and an extension meeting.

Horizon Space Acquisition II Corp. reports a net loss for Q1 2026, with significant redemptions and ongoing efforts to complete a business combination.

Horizon Space Acquisition II Corp. reported a net income of $615,026 for Q3 2025, driven by trust account interest, but faces going concern doubts amid a pending merger with SL Bio Ltd.

Horizon Space Acquisition II Corp. announced a definitive business combination agreement with SL Bio Ltd., a cellular and gene therapy developer, while facing significant liquidity challenges.

Horizon Space Acquisition II Corp. reports a net income of $472,592 for the quarter ended March 31, 2025, and announces a business combination agreement with SL Bio Ltd.

Horizon Space Acquisition II Corp. reports a net loss of $33,604 for the three months ended September 30, 2024, and provides an update on its search for a business combination target.

Horizon Space Acquisition II Corp. has filed its 2025 Form 10-K, detailing its ongoing efforts to complete a business combination and its financial status.

Horizon Space Acquisition II Corp. reports a net income of $142,877 for the year ended December 31, 2024, primarily from interest income on the Trust Account.

CEO Mingyu Li files an exit Form 4 following the consummation of Horizon Space Acquisition II Corp.'s initial business combination.

Cai Tianchen voluntarily files Form 4 to report no longer serving as director or holding shares of Horizon Space Acquisition II Corp. after its business combination on June 12, 2026.

Chief Financial Officer Zhai Min has ceased serving as an officer of Horizon Space Acquisition II Corp. following the company's business combination.

Director Qian Xu has ceased serving on the board of Horizon Space Acquisition II Corp. following the company's business combination.

Horizon Space Acquisition II Corp. announced a $7.8 million PIPE financing to support its business combination with SL BIO Ltd., forming SL Science Holding Limited.

Horizon Space Acquisition II Corp. announced a $7.8 million private investment in public equity (PIPE) financing to support its business combination with SL BIO Ltd., forming SL Science Holding Limited.

Horizon Space Acquisition II Corp. (HSPT) is seeking shareholder approval to extend its business combination deadline to February 2027 to complete its proposed merger with SL Bio Ltd. or an alternative.

Horizon Space Acquisition II Corp. filed an 8-K to correct and clarify proxy statement details for its upcoming business combination vote with SL BIO Ltd., focusing on redemption procedures and contact information.

Horizon Space Acquisition II Corp. (HSPT) announces a definitive business combination agreement with SL BIO Ltd. (SL Bio), valuing SL Bio at $5.568 billion, with the combined entity, PubCo, to list on Nasdaq under 'SLBT'.

Horizon Space Acquisition II Corp., a blank check company with ties to China, files an amendment to its S-1 registration statement for a proposed $60 million initial public offering.

Horizon Space Acquisition II Corp., a blank check company with ties to China, aims to raise $60 million through an IPO to pursue a merger, share exchange, asset acquisition, or similar business combination.

Horizon Space Acquisition II Corp. has finalized its business combination with SL Bio Ltd., resulting in the reporting persons exiting their positions.

Mizuho Financial Group, Inc. has granted power of attorney to Takahiro Katsura for executing and filing Form 13G with the SEC.

Wolverine Asset Management and affiliates report 0% beneficial ownership in Horizon Space Acquisition II Corp. in latest SEC filing.

Bank of Montreal and its affiliates report 0% beneficial ownership of Horizon Space Acquisition II Corp. ordinary shares in an amended Schedule 13G filing.

Boothbay Fund Management and related entities have filed an amended Schedule 13G, reporting zero beneficial ownership in Horizon Space Acquisition II Corp. ordinary shares.

Mizuho Financial Group, Inc. has disclosed a 6.9% beneficial ownership stake in Horizon Space Acquisition II Corp. common shares.

W. R. Berkley Corporation and its subsidiary Berkley Insurance Company reported a 7.4% beneficial ownership stake in Horizon Space Acquisition II Corp.